Japan Bladder Cancer Market Growth, Analysis Report, Share, Trends and Overview 2022-2028
Japan
bladder cancer market is estimated to grow modestly at a CAGR of around 10.2%
during the forecast period. Due to the well-established healthcare industry and
awareness about bladder cancer and its treatment, the opportunities for drugs
and devices for bladder cancer exist substantially in Japan. The mortality
caused due to cancer in Japan is estimated to around 0.37 million in 2017.
According to the Tsugane’s contribution to cancer research, the Population
Attributable Fraction (PAF) of tobacco smoking to cancer was 24%, alcohol
drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50%
of cancer death were not sufficiently clarified.
To learn more about this report request a sample
copy @ https://www.omrglobal.com/request-sample/japan-bladder-cancer-market
Japan
bladder cancer market is segmented into cancer type, diagnosis, and treatment.
Based on cancer type, the market is segmented into transitional cell bladder
cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and
other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the
market is segmented into cystoscopy, biopsy, urinalysis, urine cytology,
intravenous pyelogram (IVP), and others. Based on treatment, the market is
segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and
other treatment which include targeted therapy. The cystoscopy procedure is the
most used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be
passed through cystoscope to treat exceedingly small bladder tumors, which might
be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis
of the disease.
A full report of Japan Bladder Cancer Market is
available at: https://www.omrglobal.com/industry-reports/japan-bladder-cancer-market
The
companies which are contributing to the growth of the Japan bladder cancer
market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co.,
GlaxoSmithKline PLC, Sysmex Corp., and Pfizer, Inc. The market players are
considerably contributing to the market growth by the adoption of various
strategies including new product launch, merger, and acquisition,
collaborations with government, funding to the start-ups, and technological advancements
to stay competitive in the market.
Japan Bladder Cancer Market- Segmentation
By
Cancer type
·
Transitional Cell Bladder Cancer/ Urothelial
Carcinoma
·
Squamous Cell Bladder Cancer
·
Adenocarcinoma
·
Other Rare Types (Sarcomas, Carcinoma in Situ)
By
Diagnosis Method
·
Cystoscopy
·
Biopsy
·
Urinalysis
·
Urine Cytology
·
Intravenous Pyelogram (Ivp)
·
Other
By
Therapy
·
Chemotherapy
·
Immunotherapy
·
Radiation Therapy
·
Surgery
·
Other
Company Profiles
·
Astellas Pharma
Inc.
·
AstraZeneca PLC
·
Bayer AG
·
Bristol-Myers
Squibb Co.
·
Eli Lilly and Co.
·
F. Hoffmann-La
Roche AG
·
GlaxoSmithKline Plc
·
Johnson &
Johnson Services, Inc.
·
Merck KGaA
·
Pfizer Inc.
·
Sysmex Corp.
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more
than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and
after purchasing your report.
About Orion Market Research
Orion
Market Research (OMR) is a market research and consulting company known for its
crisp and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services.
Media Contact:
Contact
Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no:
+91 780-304-0404
Company
Name: Orion Market Research
0 Comments